Head of Group Benefits Enrollment and Billing Technology
The Guardian Life Insurance Company of America is hiring for Head of Group Benefits Enrollment and Billing Technology in Holmdel. Hybrid, Executive level, $155k–$255k a year stated. First seen November 6, 2026; open as of November 13, 2026. Jobs taken straight from company career pages — no aggregator in between.
With Destava: How well do you fit? · Tailor my résumé · Write a cover letter
- Company
- The Guardian Life Insurance Company of America
- Where
- Holmdel, Bethlehem, New York
- Arrangement
- Hybrid
- Level
- Executive
- Pay stated
- $155k–$255k a year
- First seen
- November 6, 2026
- Listed via
- Workday
What the posting says
Head of Group Benefits Enrollment and Billing Technology Position Overview As the Head of Group Benefits Enrollment and Billing Technology, you will serve as the strategic and technical leader for the capabilities that onboard members, manage eligibility and enrollment, and enable accurate, timely billing across the Group Benefits value stream. You will guide multiple products and squads while partnering closely with business product managers and owners to shape and execute a modern technology vision. Your leadership will simplify complex processes, modernize core platforms, strengthen data…
Read more and apply on The Guardian Life Insurance Company of America's site
More jobs like this
Total Rewards Associate
Save to applyTotal Rewards Associate
Save to applyTotal Rewards Associate
Save to applyTotal Rewards Associate
Save to apply
See all 1,073 Compensation and Benefits Managers jobs
A search agent finds the jobs this list misses: the ones that mean the same without the same words. Have Destava watch for head of group benefits enrollment and billing technology jobs in Holmdel, new matches every morning on your own account.
This page includes information from the O*NET 31.0 Database by the U.S. Department of Labor, Employment and Training Administration (USDOL/ETA). Used under the CC BY 4.0 license. O*NET® is a trademark of USDOL/ETA.